Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations · BEDMINSTER · NJ
Moderate confidence (50%)
Updated Oct 9, 2026, 12:04 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: Matinas BioPharma Holdings, Inc. received a delisting notice from its exchange (Aug 31, 2026)
Timeline
Every material event, newest first. History is never overwritten.
Matinas BioPharma Holdings, Inc. received a delisting notice from its exchange
Aug 31, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 31, 2026, Matinas BioPharma Holdings, Inc. (the Company ) received written notice (the Notice ) from the NYSE American LLC (the NYSE American ) that it is not in compliance with the continued listing standard set forth in Section 1003(a)(i) of the NYSE American Company Guide (the Company Guide ), which requires a company to have stockholders equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent…”
Matinas BioPharma Holdings, Inc. received a delisting notice from its exchange
Jun 24, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed under Item 3.01 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 3, 2026, Matinas BioPharma Holdings, Inc. (the Company ) received a written notice (the April Notice ) from the NYSE American LLC (the NYSE American ) indicating that the Company was not in compliance with the NYSE American continued listing standard set forth in Section 1003(a)(iii) of the NYSE American Company Guide (the Company Guide ) requiring a co…”
Matinas BioPharma Holdings, Inc. received a delisting notice from its exchange
Apr 2, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 2, 2026, Matinas BioPharma Holdings, Inc. (the Company ) received a written notice (the Notice ) from the NYSE American LLC (the NYSE American ) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the Company Guide ) requiring a company to have stockholders equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Pharmaceutical Preparations
- Subindustry
- —
- Listing
- SEC lists the ticker MTNB on NYSE.
- SEC CIK
- 0001582554
- Website
- —
- —
- Headquarters
- BEDMINSTER, NJ
- Also known as
- —
- Legal entities
- Matinas BioPharma Holdings, Inc.
Sources
Every material source used to build this profile.
SEC Company Submissions (TIER 1 · UNVERIFIED)
Matinas BioPharma Holdings, Inc. — Pharmaceutical Preparations (SIC 2834) — BEDMINSTER, NJ
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 2, 2026, Matinas BioPharma Holdings, Inc. (the Company ) received a written notice (the Notice ) from the NYSE American LLC (the NYSE American ) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the Company Guide ) requiring a company to have stockholders equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed under Item 3.01 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 3, 2026, Matinas BioPharma Holdings, Inc. (the Company ) received a written notice (the April Notice ) from the NYSE American LLC (the NYSE American ) indicating that the Company was not in compliance with the NYSE American continued listing standard set forth in Section 1003(a)(iii) of the NYSE American Company Guide (the Company Guide ) requiring a co…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 31, 2026, Matinas BioPharma Holdings, Inc. (the Company ) received written notice (the Notice ) from the NYSE American LLC (the NYSE American ) that it is not in compliance with the continued listing standard set forth in Section 1003(a)(i) of the NYSE American Company Guide (the Company Guide ), which requires a company to have stockholders equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent…
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:30 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:11 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:33 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:45 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 02:39 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.